Skip to content

Clinico-Genomic Database

Flatiron and Foundation Medicine’s real-world Clinico-Genomic Database (CGDB) integrates de-identified clinical data from electronic health records with comprehensive genomic profiling data.

CGDB

Connect genomics with clinical outcomes

The CGDB allows researchers to accelerate precision oncology studies. Providing clinically meaningful data on 300+ genes sourced from 100k+ patient records, the CGDB enables both disease-specific and disease-agnostic analyses. Patient data from early through metastatic disease stages are included in the majority of datasets, with up to 3-month recency.  


Features

Unlocking insights: Flatiron’s disease-specific and agnostic real-world data models

Disease-specific data models


The CGDB includes data on 20 disease types:

  • Acute myeloid leukemia

  • Advanced bladder cancer

  • Breast cancer

  • Chronic lymphocytic leukemia

  • Colorectal cancer

  • Diffuse large B-Cell lymphoma

  • Advanced endometrial cancer

  • Follicular lymphoma

  • Gastric/Esophageal/GEJ cancer

  • Head and neck cancer

  • Hepatocellular carcinoma

  • Mantle cell lymphoma

  • Melanoma

  • Multiple myeloma

  • Non-small cell lung cancer

  • Ovarian cancer

  • Pancreatic cancer

  • Metastatic prostate cancer

  • Renal cell carcinoma

  • Small cell lung cancer

Disease-agnostic data models


Our disease-agnostic datasets combine 20 disease-specific data models with a lighter-weight data model for all other histologies to enable robust pan-tumor analyses.

Comprehensive genomic profiling


The CGDB contains robust genomic profiling data across solid and liquid biopsies utilizing circulating tumor DNA (ctDNA), and offers complex biomarker information such as tumor mutational burden (TMB), microsatellite instability (MSI) status, and PD-L1 results.

By the numbers

100k+

Patients linked in the CGDB

300+

Genes in the CGDB

100+

Publications enabled with 15+ biopharma partners


“Originally stemming from a high-priority need for real-world data, we were able to foster a new collaboration with Flatiron and Foundation Medicine and utilize their large data source of rich clinical and genomic data, representing a substantial proportion of community oncology patients nationally.”

Hil Hsu, PhD, MPH

Senior Manager, Center for Observational Research

Amgen

Source: ResearchX
 
downloadable-pdf-flatiron-1

Featured Resource

Real-world evidence use cases

Learn how the CGDB and other Flatiron real-world evidence solutions can inform key clinical development decisions, support regulatory submissions, fulfill post-marketing commitments, accelerate patient access, and more.

Derive real-world endpoints using validated outcome variables

CGDB-Icon-01

Real-world overall survival

Conduct robust survival analyses with our validated mortality variable, available with all CGDB subscriptions.

CGDB-Icon-02

Real-world progression-free survival

Analyze real-world progression-related endpoints across observational RWE studies with our validated real-world progression (rwP) variable, available with certain CGDB subscriptions. 

CGDB-Icon-03

Real-world response endpoints

Analyze real-world response-related endpoints to support clinical development or regulatory decision making with our validated real-world response (rwR) variable, available with certain CGDB subscriptions. 

Icon

fact sheet

Clinico-Genomic Database fact sheet

Explore more integrated real-world evidence products

Flatiron’s customizable real-world data products integrate EHR-derived data with other data modalities.

Products and services include:

Get in touch

Learn more about the Clinico-Genomic Database.